Division of Immunology, Allergy and Retrovirology, Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston, Texas.
St. John's Institute of Dermatology, King's College London, and Guy's & St. Thomas' NHS Foundation Trust, London, UK.
J Allergy Clin Immunol Pract. 2023 May;11(5):1376-1383. doi: 10.1016/j.jaip.2023.03.041. Epub 2023 Mar 29.
Managing atopic dermatitis (AD) in patients with skin of color presents unique challenges for the clinician. There is increasing evidence that AD has higher prevalence, persistence, and severity among skin of color populations. This is likely to be partly related to differences in living conditions and exposure to irritants and allergens, among other factors. Assessment of AD severity in patients with darker skin can be challenging, in particular the assessment of erythema, leading to the potential for underscoring AD severity. Variations in disease have also been described, with the potential for a greater risk of inflammation-induced nodularity and hyper- or hypopigmentation. Management challenges include variable adherence to treatment, potential disparities in access to health care, and differences in the metabolism of cyclosporine. Optimal management of AD in patients with skin of color requires a tailored approach. Here, we review approaches to diagnosing AD, evaluating extent and severity with subjective and objective measures, considering treatment options for patients with skin of color, and highlighting areas for improvement in AD care for skin of color populations.
管理有色人种患者的特应性皮炎(AD)给临床医生带来了独特的挑战。越来越多的证据表明,AD 在有色人种中的患病率、持续性和严重程度更高。这可能部分与生活条件的差异以及接触刺激物和过敏原等因素有关。评估深色皮肤患者的 AD 严重程度具有挑战性,特别是评估红斑,这可能导致低估 AD 的严重程度。疾病也存在变异,炎症引起的结节和过度或色素减退的风险可能更大。管理挑战包括治疗的依从性差异、获得医疗保健的机会差异以及环孢素代谢的差异。为了在有色人种患者中实现 AD 的最佳管理,需要采取个性化的方法。在这里,我们回顾了 AD 的诊断方法,使用主观和客观措施评估其范围和严重程度,考虑了针对有色人种患者的治疗选择,并强调了改善 AD 对有色人种患者护理的领域。